Role of Immunoglobulin in Male Infertility

Male Subfertility Clinical Trial

Official title:

Role of Immunoglobulin in Male Infertility

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06423989
• Other study ID #: 102023
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: May 2024
• Source: Salma Kafeel Medical Centre
• Contact: DR Riffat, PhD
• Phone: 00923225041390
• Email: rifat.skmc[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

to investigate the role of IVIG in male infertility and to determine its benefits in term of semen parameters and assisted reproduction outcome

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 1, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• male patients

Exclusion Criteria:

• female

Related Conditions & MeSH terms

• Infertility
• Infertility, Male
• Male Subfertility

Intervention

Combination Product:
• IVIG
treatment of subfertility

Locations

Country	Name	City	State
Pakistan	SKMC	Islamabad	Capital

Sponsors (1)

Lead Sponsor	Collaborator
Dr Salma kafeel Qureshi

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Semen parameters percentage improvement	Sperm concentration/ml	6 month
Primary	Sperm motility	Percentage active motile sperm	6 month
Primary	Sperm morphology	Percentage of normal sperm	6 month
Secondary	Assisted Reproduction outcome measure	Percentage of fertilized	12 months